» Articles » PMID: 23503602

Global Brain Delivery of Neprilysin Gene by Intravascular Administration of AAV Vector in Mice

Overview
Journal Sci Rep
Specialty Science
Date 2013 Mar 19
PMID 23503602
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulation of amyloid-β peptide (Aβ) in the brain is closely associated with cognitive decline in Alzheimer's disease (AD). Stereotaxic infusion of neprilysin-encoding viral vectors into the hippocampus has been shown to decrease Aβ in AD-model mice, but more efficient and global delivery is necessary to treat the broadly distributed burden in AD. Here we developed an adeno-associated virus (AAV) vector capable of providing neuronal gene expression throughout the brains after peripheral administration. A single intracardiac administration of the vector carrying neprilysin gene in AD-model mice elevated neprilysin activity broadly in the brain, and reduced Aβ oligomers, with concurrent alleviation of abnormal learning and memory function and improvement of amyloid burden. The exogenous neprilysin was localized mainly in endosomes, thereby effectively excluding Aβ oligomers from the brain. AAV vector-mediated gene transfer may provide a therapeutic strategy for neurodegenerative diseases, where global transduction of a therapeutic gene into the brain is necessary.

Citing Articles

Neprilysin-Mediated Amyloid Beta Clearance and Its Therapeutic Implications in Neurodegenerative Disorders.

Saxena S, Ansari S, Maurya V, Kumar S, Sharma D, Malhotra H ACS Pharmacol Transl Sci. 2024; 7(12):3645-3657.

PMID: 39698259 PMC: 11651204. DOI: 10.1021/acsptsci.4c00400.


Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab.

Iwata N, Tsubuki S, Sekiguchi M, Watanabe-Iwata K, Matsuba Y, Kamano N Life Sci Alliance. 2024; 7(12).

PMID: 39348937 PMC: 11443169. DOI: 10.26508/lsa.202402650.


Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications.

Ye D, Chukwu C, Yang Y, Hu Z, Chen H Adv Drug Deliv Rev. 2024; 211:115363.

PMID: 38906479 PMC: 11892011. DOI: 10.1016/j.addr.2024.115363.


A Metalloproteinase Cocktail from the Venom of Cleaves Amyloid Beta Peptides at the α-Cleavage Site.

Futai E, Kawasaki H, Sato S, Daoudi K, Hidaka M, Tomita T Toxins (Basel). 2023; 15(8).

PMID: 37624257 PMC: 10467146. DOI: 10.3390/toxins15080500.


Nucleic acid drug vectors for diagnosis and treatment of brain diseases.

Lu Z, Shen J, Yang J, Wang J, Zhao R, Zhang T Signal Transduct Target Ther. 2023; 8(1):39.

PMID: 36650130 PMC: 9844208. DOI: 10.1038/s41392-022-01298-z.


References
1.
Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K . A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther. 2010; 18(9):1731-5. PMC: 2956925. DOI: 10.1038/mt.2010.135. View

2.
Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B . Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci. 2004; 24(4):991-8. PMC: 6729819. DOI: 10.1523/JNEUROSCI.4792-03.2004. View

3.
Foust K, Nurre E, Montgomery C, Hernandez A, Chan C, Kaspar B . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2008; 27(1):59-65. PMC: 2895694. DOI: 10.1038/nbt.1515. View

4.
Selkoe D . Alzheimer's disease is a synaptic failure. Science. 2002; 298(5594):789-91. DOI: 10.1126/science.1074069. View

5.
Petrs-Silva H, Dinculescu A, Li Q, Deng W, Pang J, Min S . Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther. 2010; 19(2):293-301. PMC: 3034844. DOI: 10.1038/mt.2010.234. View